The stock of Cassava Sciences Inc (SAVA) has seen a 4.36% increase in the past week, with a -4.67% drop in the past month, and a -11.79% decrease in the past quarter. The volatility ratio for the week is 7.95%, and the volatility levels for the past 30 days are at 6.58% for SAVA. The simple moving average for the past 20 days is 4.11% for SAVA’s stock, with a 20.20% simple moving average for the past 200 days.
Is It Worth Investing in Cassava Sciences Inc (NASDAQ: SAVA) Right Now?
SAVA has 36-month beta value of -0.59. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SAVA is 41.77M, and currently, short sellers hold a 44.46% ratio of that float. The average trading volume of SAVA on November 19, 2024 was 1.64M shares.
SAVA) stock’s latest price update
Cassava Sciences Inc (NASDAQ: SAVA) has seen a decline in its stock price by -1.50 in relation to its previous close of 27.95. However, the company has experienced a 4.36% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-18 that Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs
Analysts’ Opinion of SAVA
Many brokerage firms have already submitted their reports for SAVA stocks, with H.C. Wainwright repeating the rating for SAVA by listing it as a “Buy.” The predicted price for SAVA in the upcoming period, according to H.C. Wainwright is $116 based on the research report published on October 08, 2024 of the current year 2024.
B. Riley Securities gave a rating of “Neutral” to SAVA, setting the target price at $44 in the report published on November 16th of the previous year.
SAVA Trading at 0.02% from the 50-Day Moving Average
After a stumble in the market that brought SAVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.76% of loss for the given period.
Volatility was left at 6.58%, however, over the last 30 days, the volatility rate increased by 7.95%, as shares sank -3.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.89% upper at present.
During the last 5 trading sessions, SAVA rose by +4.28%, which changed the moving average for the period of 200-days by +20.08% in comparison to the 20-day moving average, which settled at $26.44. In addition, Cassava Sciences Inc saw 22.31% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SAVA
Current profitability levels for the company are sitting at:
- -59.86 for the present operating margin
- 0.59 for the gross margin
The net margin for Cassava Sciences Inc stands at -7.52. The total capital return value is set at -0.84. Equity return is now at value -10.98, with -8.91 for asset returns.
Currently, EBITDA for the company is -95.69 million with net debt to EBITDA at 1.12. When we switch over and look at the enterprise to sales, we see a ratio of 504.53. The receivables turnover for the company is 0.37for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.55.
Conclusion
To put it simply, Cassava Sciences Inc (SAVA) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
